Business
Viveve(R) Announces Regulatory Approval for Viveve System in Brazil
Viveve(R) Announces Regulatory Approval for Viveve System in Brazil.
About this update from Viveve Medical, Inc.
[{"type":"text","content":"\nViveve(R) Announces Regulatory Approval for Viveve System in Brazil\n\nViveve(R) Announces Regulatory Approval for Viveve System in Brazil\n\n\nViveve System is now available for marketing in 48 countries around the world\n\nSUNNYVALE, CA--(Marketwired - October 20, 2016) - Viveve Medical, Inc. (\"Viveve\") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approval in Brazil. The Viveve System is indicated for treatment of the vaginal introitus after vaginal childbirth to improve sexual function.\"Regulatory clearance to market the Viveve System in Brazil is an exciting milestone for Viveve,\" said Patricia Scheller, chief executive officer of Viveve. She continued, \"As one of the largest markets in the world for aesthetic medical procedures, commercializing the Viveve System in the Brazilian market will position Viveve as a leader in supporting women's sexual health in Latin America. We are fortunate to have a strong relationship with our distribution partner in Brazil, HV Medical, and look forward to supporting their efforts to bring this clinically-proven treatment to women in the region whose sexual function and quality of life have diminished.\" About ViveveViveve Medical, Inc. is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the internationally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve System uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan. For more information, please visit Viveve's website at www.viveve.com.Safe Harbor StatementAll statements in this pr...